Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Topics	Advisory Committee	Date	Details
Nektar Therapeutics' oxycodegol for management of chronic low back pain in adults with pain severe enough to require daily around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate	Anesthetic and Analgesic Drug Products/Drug Safety and Risk Management	Jan. 14	Meeting notice
Esteve Pharmaceuticals' tramadol/celecoxib fixed-dose combination tablet for management of acute pain in adults severe enough to require an opioid analgesic and for which alternative treatments are inadequate	Anesthetic and Analgesic Drug Products/Drug Safety and Risk Management	Jan. 15 (morning)	Meeting notice
Intellipharmaceutics' oxycodone extended-release oral tablet, formulated with properties intended to deter abuse, for management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time	Anesthetic and Analgesic Drug Products/Drug Safety and Risk Management	Jan. 15 (afternoon)	Meeting notice
Durect's Posimir (bupivacaine extended-release) for post-surgical analgesia	Anesthetic and Analgesic Drug Products	Jan. 16	Meeting notice
Influenza virus vaccine strain selection recommendations for the 2020-2021 flu season; overview of the research programs in the Laboratory of Respiratory and Special Pathogens in the Division of Bacterial, Parasitic and Allergenic Products	Vaccines and Related Biological Products	March 4	Meeting notice